A modified insulin-like growth factor with reduced binding-protein affinity and a longer half-life, used widely in cell culture; human therapeutic use is not approved.
IGF-1 LR3 is a modified, longer-lasting version of insulin-like growth factor 1 (IGF-1), a hormone that drives cell growth and division. It's used mainly as a research reagent.
Two changes — a swapped amino acid and an added segment — reduce how tightly it sticks to the binding proteins that normally hold IGF-1 in check, leaving more of it free and active. Acting on the IGF-1 receptor, it switches on growth-promoting pathways (PI3K/Akt and MAPK) more potently and for longer than natural IGF-1.
That same potent growth signaling is a double-edged sword: it's the basis for anabolic interest but also a theoretical concern, since strong, sustained growth stimulation raises proliferative and cancer-related questions. It is not approved for human use.
Searching the published record…
Searching the published record…
Searching the published record…
Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.